BiotechTube

Rocuronium + Sugammadex + Neostigmine + Glycopyrrolate

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Malignant Neoplasms of Urinary Tract

Conditions

Malignant Neoplasms of Urinary Tract, Bladder Cancer

Trial Timeline

Sep 18, 2017 → Nov 24, 2019

NCT ID
NCT03138967

About Rocuronium + Sugammadex + Neostigmine + Glycopyrrolate

Rocuronium + Sugammadex + Neostigmine + Glycopyrrolate is a approved stage product being developed by Merck for Malignant Neoplasms of Urinary Tract. The current trial status is completed. This product is registered under clinical trial identifier NCT03138967. Target conditions include Malignant Neoplasms of Urinary Tract, Bladder Cancer.

What happened to similar drugs?

4 of 20 similar drugs in Malignant Neoplasms of Urinary Tract were approved

Approved (4) Terminated (2) Active (14)
✅Deep Neuromuscular Blockade (NMB) + Moderate Neuromuscular Blockade (NMB) + Sugammadex + NeostigmineMerckApproved
✅ZelborafRocheApproved
✅Atezolizumab Injection [Tecentriq]RocheApproved
✅Fibrin Sealant (Tisseel) used in the Experimental Arm.BaxterApproved
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
🔄Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
🔄Ropivacaine + Epinephrine + Decadron + Clonidine + PropofolMerckPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03138967ApprovedCompleted

Competing Products

20 competing products in Malignant Neoplasms of Urinary Tract

See all competitors
ProductCompanyStageHype Score
liposomal irinotecan monotherapy + liposomal irinotecan monotherapy + Liposomal Irinotecan + rmhTNF-NC + Liposomal Irinotecan + BevacizumabCSPC Pharmaceutical Group LimitedPhase 1/2
39
Fulvestrant + AbemaciclibEli LillyPhase 2
39
Tadalafil + GemcitabineEli LillyPhase 1
29
Patritumab DeruxtecanDaiichi SankyoPhase 1/2
39
Tivantinib + FOLFOXDaiichi SankyoPhase 1/2
32
DS-1123Daiichi SankyoPhase 1
29
DS-8201aDaiichi SankyoPhase 1
29
DS-5573aDaiichi SankyoPhase 1
21
DS-6051bDaiichi SankyoPhase 1
29
U3-1565Daiichi SankyoPhase 1
29
MK-1084 + Patritumab deruxtecan + Sacituzumab tirumotecan + Cetuximab + Rescue MedicationsDaiichi SankyoPhase 1/2
39
DS-3201b + DS-3201bDaiichi SankyoPhase 1
33
DS-8895a 1 mg/kg + DS-8895a 3 mg/kg + DS-8895a 10 mg/kgDaiichi SankyoPhase 1
29
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
39
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
39
CP-461Astellas PharmaPhase 2
27
enfortumab vedotinAstellas PharmaPhase 1
29
LNF1901 Monoclonal Antibody InjectionSun PharmaceuticalPhase 1
36
Perampanel + Standard of CareEisaiPhase 1/2
32
Pembrolizumab + Lenvatinib + Placebo for lenvatinibEisaiPhase 3
40